Trials / Unknown
UnknownNCT06152822
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases：a Single-arm,Prospective,Phase II Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study intends to conduct a small, prospective, single-center clinical study to explore and evaluate the efficacy and safety of pyrrotinib combined with capecitabine and bevacizumab in HER2-positive advanced breast cancer with brain metastases.The overall objective is to provide a new drug regimen for HER2 positive breast cancer patients with brain metastases by balancing survival benefits and patient quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pyrotinib+capecitabine+bevacizumab | pyrotinib: ≥160mg qd capecitabine: 1000mg/m2,bid,q1-14,q3w bevacizumab:7.5mg/kg,iv,q3w |
Timeline
- Start date
- 2023-11-30
- Primary completion
- 2024-11-30
- Completion
- 2025-11-30
- First posted
- 2023-12-01
- Last updated
- 2023-12-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06152822. Inclusion in this directory is not an endorsement.